SCHEMBL3013300

SCHEMBL3013300

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.52
LMNA P02545 5/20 0.52
KMT2A Q03164 5/20 0.52
MAPK1 P28482 4/20 0.52
MAPT P10636 7/20 0.52
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ALDH1A1 P00352 7/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
ALDH3A1 P30838 1/20 0.49
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
NPSR1 Q6W5P4 3/20 0.45
GAA P10253 1/20 0.45
AR P10275 1/20 0.44
TSHR P16473 2/20 0.44
POLB P06746 1/20 0.44
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015002 0.92 LMNA (0.52) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3020343 0.91 SMN1; SMN2 (0.49) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3017906 0.90 MAPT (0.56) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3018215 0.90 MAPT (0.54) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3019901 0.89 SMN1; SMN2 (0.54) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3015861 0.89 MAPK1 (0.63) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3016174 0.88 MEN1 (0.50) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3006873 0.88 LMNA (0.52) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3013695 0.88 MAPT (0.63) MEN1LMNAKMT2AMAPK1MAPT
SCHEMBL3010739 0.88 AR (0.52) MEN1LMNAKMT2AMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885LMNA 80/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.